Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · IEX Real-Time Price · USD
1.750
-0.060 (-3.31%)
Jul 22, 2024, 11:16 AM EDT - Market open
Entera Bio Employees
As of December 31, 2023, Entera Bio had 18 total employees, including 17 full-time and 1 part-time employees. The number of employees increased by 1 or 5.88% compared to the previous year.
Employees
18
Change (1Y)
1
Growth (1Y)
5.88%
Revenue / Employee
n/a
Profits / Employee
-$484,222
Market Cap
62.14M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Prenetics Global | 324 |
| Celularity | 225 |
| Vor Biopharma | 168 |
| Allakos | 131 |
| ProPhase Labs | 113 |
| MSP Recovery | 88 |
| InspireMD | 66 |
| SELLAS Life Sciences Group | 16 |
ENTX News
- 2 months ago - Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member - GlobeNewsWire
- 2 months ago - Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 - GlobeNewsWire
- 2 months ago - Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research - GlobeNewsWire
- 4 months ago - Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months - GlobeNewsWire
- 4 months ago - Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome - GlobeNewsWire
- 4 months ago - Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire